[关键词]
[摘要]
慢性淋巴细胞白血病( chronic lymphocytic leukemia，CLL) 是一种成熟B 淋巴细胞克隆增殖性肿瘤，
以淋巴细胞在外周血、骨髓、脾脏和淋巴结聚集为特征。目前的标准治疗方案是氟达拉滨+环磷酰胺+利妥昔单
抗的FCR 方案。作为首个靶向药物，B 细胞受体信号通路抑制剂极大的改变了CLL 的治疗。Venetoclax 是由
AbbVie 公司和Genentech /Roche 公司合作研发的口服选择性抗凋亡蛋白Bcl－2 抑制剂，现已被FDA 批准用于
17p 染色体缺失的CLL 病人。它是唯BH3 蛋白( Bcl－2 蛋白家族成员) 的类似物，可以重建恶性肿瘤细胞的凋亡
通路。目前，Venetoclax 与其他药物联合治疗CLL 的I－III 期临床试验、单用或联合其他药物治疗非霍奇金淋巴
瘤和急性白血病的I /II 期临床试验也在进行当中。本文叙述了Venetoclax 全方面的研究进展。
[Key word]
[Abstract]
Chronic lymphocytic leukemia ( CLL ) is a kind of mature B lymphocyte clone
hyperplastic tumor that characterized by aggregation lymphocytes in peripheral blood，bone marrow，
spleen and lymph nodes，and treated by chemoimmunotherapy，typically with fludarabine，cyclophosphamide，
and rituximab(FCR) as a standard therapy currently．Inhibitors of B cell receptor signaling dramaticlly
changed the treatment of CLL as the first targeted agents to enter routine clinical practice．
Venetoclax，an oral selective inhibitor of the antiapoptotic protein Bcl－2co－developed by AbbVie and
Genentech /Roche，is a BH 3 mimetic approved for treating chronic lymphocytic leukemia with the 17p
deletion in the USA which restores the apoptotic ability of malignant cells．Venetoclax is also in phase I
－III development as combination therapy for CLL，phase I /II development as monotherapy and /or combination
therapy for non－Hodgkin lymphomas and acute myeloid leukaemia．This article summarizes the
development of Venetoclax on all sides．
[中图分类号]
R961
[基金项目]
收稿日期: 2017－01－11;修回日期: 2017－03－12
基金项目: 内蒙古自治区科技计划项目(kjt15sf24)
作者简介: 李晓娟(1986－)，女，内蒙古医科大学附属医院药剂部药师。
通讯作者: 解红霞，主任药师，教授，药学博士，硕士研究生导师，E－mail:xiehongxia2004@ sohu．com 内蒙古医科大学附
属医院药剂部，010050
